Compare · ADOC vs BIIB
ADOC vs BIIB
Side-by-side comparison of Edoc Acquisition Corp. (ADOC) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADOC and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $33.08B, about 273.4x ADOC ($121.0M).
- BIIB has hit the wire 9 times in the past 4 weeks while ADOC has been quiet.
- BIIB has more recent analyst coverage (25 ratings vs 0 for ADOC).
- Company
- Edoc Acquisition Corp.
- Biogen Inc.
- Price
- $2.81-63.97%
- $184.16-2.00%
- Market cap
- $121.0M
- $33.08B
- 1M return
- -
- -2.67%
- 1Y return
- -
- +54.72%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
Edoc Acquisition Corp.
Edoc Acquisition Corp. is a blank check company. The company intends to focus on businesses primarily operating in the health care and health care provider space in North America and the Asia-Pacific. Edoc Acquisition Corp. was incorporated in 2020 and is based in Victor, New York.
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest ADOC
- SEC Form 15-12G filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 25-NSE filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 425 filed by Edoc Acquisition Corp.
- SEC Form 425 filed by Edoc Acquisition Corp.
- Edoc Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Edoc Acquisition Corp. Announces Postponement Of Special Meeting Of Shareholders On Proposed Business Combination
- Edoc Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
- SEC Form 425 filed by Edoc Acquisition Corp.
Latest BIIB
- FDA Approval for ZURZUVAE issued to BIOGEN INC
- Biogen upgraded by UBS with a new price target
- Biogen upgraded by Wells Fargo with a new price target
- TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
- Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
- Biogen upgraded by Piper Sandler with a new price target
- Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
- Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
- Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- SEC Form 4 filed by Godbout Sean